Former Chief Executive Officer, Celgene Cellular Therapeutics and Executive Vice President, Celgene Corporation
Perry Karsen was the Chief Executive Officer of Celgene Cellular Therapeutics from 2013 until his retirement in 2015. Previously, Perry held the position of Executive Vice President and Chief Operations Officer at Celgene, serving in various management positions, including Senior Vice President and Head of Worldwide Business Development and President of Asia/Pacific region. Prior to Celgene, Perry was the President and Chief Executive Officer of Pearl Therapeutics, a biotechnology company subsequently acquired by Astra-Zeneca. In addition, Perry held executive positions at Human Genome Sciences, Bristol-Myers Squibb, Genentech and Abbott Laboratories earlier in his career. He also was a General Partner at Pequot Ventures focusing on investments in biotechnology and medical devices.
Perry has a BS in Biological Sciences from the University of Illinois, Urbana, a Master of Arts in Teaching Biology from Duke University, and a Masters of Management from the Kellogg School of Management at Northwestern University. Perry serves on the Board of Directors and as Chair of several private and public biotechnology companies, The Gladstone Foundation, and The Sonoma Land Trust. He is a former member of the Board of Directors and the Executive Committee of the Biotechnology Innovation Organization (BIO) and a past member of the Board of Directors of the Alliance for Regenerative Medicine (ARM).
Perry resides in Occidental, California with his wife, Melanie; they have two grown children.
Partner: Melanie A. Karsen